The β‐secretase (BACE) inhibitor NB‐360 in preclinical models: From amyloid‐β reduction to downstream disease‐relevant effects
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Inhibition of β‐secretase 1 (BACE‐1; also known as β‐site amyloid precursor protein‐cleaving enzyme‐1) is a current approach to fight the amyloid‐β (Aβ) deposition in the brains of patients with Alzheimer's disease, and a number of BACE‐1 inhibitors are being tested in clinical trials. The BACE‐1 inhibitor NB‐360, although not a clinical compound, turned out to be a valuable pharmacological tool to investigate the effects of BACE‐1 inhibition on the deposition of different Aβ species in amyloid precursor protein (APP) transgenic mice. Furthermore, chronic animal studies with NB‐360 revealed relationships between BACE‐1 inhibition, Aβ deposition, and Aβ‐related downstream effects on neuroinflammation, neuronal function, and markers of neurodegeneration. NB‐360 effects on the processing of physiological BACE‐1 substrates as well as on nonenzymatic BACE‐1 functions have been investigated, complementing studies in BACE‐1 knockout mice. Because NB‐360 is also an inhibitor for BACE‐2, nonclinical studies in adult animals revealed physiological effects of BACE‐2 inhibition. Linked Articles: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Furthermore, major severe side effects of Aβ‐directed immunotherapies are vasogenic oedema and cerebral microhaemorrhage (Mo, Li, Yang, Liu, & Feng, 2017; Salloway et al., 2014; Sperling et al., 2012).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“…mutation carriers, and the rate of Aβ clearance is reduced by 30% in sporadic AD patients (Mawuenyega et al., 2010; Potter et al., 2013), whereas a 30% lower Aβ production rate in carriers of the APP A673T variant results in protection from AD (Jonsson et al., 2012; Martiskainen et al., 2017).”
BackgroundMembrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 1×
“The APPPS1 mouse line carries the PS‐1 L166P mutation, and the APP23xPS45 mice contain the PS‐1 G384A mutation (Busche et al., 2008; Radde et al., 2006).”
BackgroundSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“These findings led to the implementation for regular clinical MRI monitoring for amyloid‐directed therapies (Sperling et al., 2011) In addition, the Food and Drug Administration initially requested to evaluate amyloid‐directed therapies, including BACE inhibitors, for their risk to induce…”
BackgroundBusche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., & Konnerth, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206171109 · Cited by 715
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · cited 1×
“Very recently, it was shown that 18‐months of treatment with the potent BACE inhibitor verubecestat in mild‐to‐ moderate AD patients did lead to a small but measurable reduction of Aβ load, measured with the PET ligand flutemetamol (Egan et al., 2018).”
BackgroundHaass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592 · cited 7×
“Note: Aβ: amyloid‐β. NB‐360 was dosed to mice carrying both the APP “Arctic” and “Swedish” mutation (tg‐ArcSwe mice; Lord et al., 2006).”
BackgroundInfluentialMicroglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease
Cai, Z., Hussain, M. D., & Yan, L.-J. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.833510 · Cited by 583
Ohno, M., Sametsky, E. A., Younkin, L. H., Oakley, H., Younkin, S. G., Citron, M., Vassar, R., & Disterhoft, J. F. (2004) · Neuron · doi:10.1016/s0896-6273(03)00810-9 · Cited by 549
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 1×
“Furthermore, major severe side effects of Aβ‐directed immunotherapies are vasogenic oedema and cerebral microhaemorrhage (Mo, Li, Yang, Liu, & Feng, 2017; Salloway et al., 2014; Sperling et al., 2012).”
BackgroundBacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435
Self-citationExpression Analysis of BACE2 in Brain and Peripheral Tissues
Bennett, B. D., Babu-Khan, S., Loeloff, R., Louis, J.-C., Curran, E., Citron, M., & Vassar, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002688200 · Cited by 317 · cited 2×
“There is considerable peripheral BACE‐2 expression in most tissues (Bennett et al., 2000), where it is involved in different proteolytic processes (Casas et al.”
BackgroundMicroglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236 · cited 2×
“has shown that rather subtle changes in the human Aβ kinetics can lead to accelerated deposition and AD: The rate of Aβ production is increased by 24% in familial mutation carriers, and the rate of Aβ clearance is reduced by 30% in sporadic AD patients (Mawuenyega et al., 2010; Potter et al., 2013), whereas a 30% lowe…”
BackgroundThe Development of Amyloid β Protein Deposits in the Aged Brain
Thal, D. R., Capetillo-Zarate, E., Del Tredici, K., & Braak, H. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.6.re1 · Cited by 234
Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells
Rochin, L., Hurbain, I., Serneels, L., Fort, C., Watt, B., Leblanc, P., Marks, M. S., De Strooper, B., Raposo, G., & van Niel, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220748110 · Cited by 186
Impaired default network functional connectivity in autosomal dominant Alzheimer disease
Chhatwal, J. P., Schultz, A. P., Johnson, K., Benzinger, T. L. S., Jack, C., Ances, B. M., Sullivan, C. A., Salloway, S. P., Ringman, J. M., Koeppe, R. A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a1aafe · Cited by 179 · cited 1×
“…of wild‐type mice, there was a strong temporal correlation between the neuronal activity patterns of the various areas of the brain (occipital, somatosensory, motor, and frontal regions), reminiscent of the default network activity observed in humans (Busche et al., 2015; Chhatwal et al., 2013).”
BackgroundRoberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143 · cited 1×
“…mouse models for Aβ accumulation with a deposition rate of approximately 1.7 μg Aβ40·g−1 brain tissue·month−1, but compared with the rate of Aβ deposition in the human AD brain (0.02 μg·g−1 tissue·month−1; Roberts et al., 2017), the rate of Aβ deposition in APP51/16 mice is around 100‐fold faster.”
InfluentialCai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101084 · Cited by 136 · cited 2×
“out mice displayed a hypopigmented phenotype (Cai et al., 2012; Dominguez et al., 2005; Shimshek et al., 2016).”
BackgroundBACE inhibition-dependent repair of Alzheimer’s pathophysiology
Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708106114 · Cited by 125 · cited 5×
“Finally, in a study in APP23xPS45 mice, the treatment started when the mice were already 6–7 months old and continued for 1.5 months (Keskin et al., 2017).”
BackgroundInfluentialSelf-citationZhu, K., Xiang, X., Filser, S., Marinković, P., Dorostkar, M. M., Crux, S., Neumann, U., Shimshek, D. R., Rammes, G., Haass, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.023 · Cited by 107 · cited 1×
“Although no human data are currently available, a study with NB‐360 in mice has shown an effect on the processing of the SEZ‐6, and a SEZ‐6‐related effect on dendritic spine dynamics, with a treatment‐related reduction of spine density (Zhu et al., 2018).”
BackgroundSelf-citationImaging of cerebrovascular pathology in animal models of Alzheimer's disease
Klohs, J., Rudin, M., Shimshek, D. R., & Beckmann, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00032 · Cited by 82
Self-citationDecreased plasma β‐amyloid in the Alzheimer's disease APP A 673 Tvariant carriers
Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M. (2017) · Annals of Neurology · doi:10.1002/ana.24969 · Cited by 64 · cited 1×
“…mutation carriers, and the rate of Aβ clearance is reduced by 30% in sporadic AD patients (Mawuenyega et al., 2010; Potter et al., 2013), whereas a 30% lower Aβ production rate in carriers of the APP A673T variant results in protection from AD (Jonsson et al., 2012; Martiskainen et al., 2017).”
BackgroundSchelle, J., Häsler, L. M., Göpfert, J. C., Joos, T. O., Vanderstichele, H., Stoops, E., Mandelkow, E., Neumann, U., Shimshek, D. R., Staufenbiel, M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.005 · Cited by 40
Self-citation
Cited by
Hijazi, S., Heistek, T. S., Scheltens, P., Neumann, U., Shimshek, D. R., Mansvelder, H. D., Smit, A. B., & van Kesteren, R. E. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0483-4 · Cited by 216
Self-citationJohnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
“The BACEi NB-360 [71, 72] was obtained from Novartis Institutes for BioMedical Research.”
MethodInfluentialSelective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae
Rother, C., Uhlmann, R. E., Müller, S. A., Schelle, J., Skodras, A., Obermüller, U., Häsler, L. M., Lambert, M., Baumann, F., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34538-5 · Cited by 28
Self-citationIs It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“Novel compounds have been synthesized and tested towards BACE1 activity, including selective or multi-target drugs, natural compounds, and their derivatives [182-186].”
Background
Metadata
- Authors
- Neumann, U., Machauer, R., & Shimshek, D. R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2019-03-10
- Volume
- 176
- Issue
- 18
- Pages
- 3435-3446
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2909381348
- Cited by
- 28
- References
- 29
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.